EXHIBIT 99.1



Investors:                                               Media:
Ann Tanabe                                               Daniel Budwick
Encysive Pharmaceuticals                                 BMC Communications
(713) 796-8822                                           (212) 477-9007 ext. 14

Hershel Berry
The Trout Group
(415) 392-3385


FOR IMMEDIATE RELEASE


   ENCYSIVE PHARMACEUTICALS ANNOUNCES CLOSING OF $36.5 MILLION STOCK OFFERING


HOUSTON, TX - (SEPTEMBER 13, 2004) - Encysive Pharmaceuticals (NASDAQ: ENCY)
announced today the closing of its previously announced offering of 4,000,000
shares of its common stock in an underwritten offering by Wachovia Capital
Markets, LLC. At the closing, Wachovia also purchased an additional 600,000
shares of common stock pursuant to its previously exercised over allotment
option. The shares of common stock were sold to the public for $7.94 per share.
With the exercise of the over allotment option, the gross proceeds from the
offering realized by Encysive is approximately $36.5 million.

The net proceeds of the offering will be used for further clinical development,
marketing and pre-launch activities related to Thelin(TM), research and
development of Encysive's other product candidates, and general corporate
purposes, including capital expenditures and other working capital requirements.

This press release shall not constitute an offer to sell or the solicitation of
an offer to buy, nor shall there be any sale of these securities in any
jurisdiction in which such offer, solicitation or sale would be unlawful prior
to the registration or qualification under the securities laws of any such
jurisdiction. Copies of the prospectus supplement can be obtained from the
Prospectus Department of Wachovia Securities (7 Saint Paul Street, 1st Floor,
Baltimore, MD 21202, phone 443-263-6400) or from Encysive (6700 West Loop, 4th
Floor, Bellaire, TX 77401, phone 713-796-8822).

ABOUT ENCYSIVE PHARMACEUTICALS

Encysive Pharmaceuticals Inc., a biopharmaceutical company focused on the
discovery, development and commercialization of novel drugs, is recognized for
our expertise in small molecule drug development and vascular biology.
Argatroban, our first FDA-approved product, is being marketed by GlaxoSmithKline
for heparin-induced thrombocytopenia. Encysive Pharmaceuticals is in Phase III
development of the endothelin antagonist, Thelin, for pulmonary arterial
hypertension. Our majority-owned affiliate, Revotar Biopharmaceuticals AG, is in
Phase II development with the selectin antagonist bimosiamose in asthma,
psoriasis and atopic dermatitis. Encysive Pharmaceuticals has several other
research and development programs ongoing for a range of cardiovascular and
inflammatory diseases. To learn more about Encysive Pharmaceuticals please visit
our web site: www.encysive.com.

This press release contains "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E of the
Securities Exchange Act of 1934, as amended. These forward-looking statements
are subject to certain risks, trends and uncertainties that could cause actual
results to differ materially from those projected. Among those risks, trends and
uncertainties are timing and cost of our clinical trials, attainment of research
and clinical goals and milestones of product candidates, attainment of required
government approvals, sales levels of our products and availability of financing
and revenues sufficient to fund development of product candidates and
operations. In particular, careful consideration should be given to cautionary
statements made in the various reports Encysive Pharmaceuticals, including as
Texas Biotechnology Corporation, has filed with the Securities and Exchange
Commission. The Company undertakes no duty to update or revise these
forward-looking statements.

                                      # # #